Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference
12. April 2023 07:30 ET
|
Zynerba Pharmaceuticals, Inc.
Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically...
Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference
05. April 2023 07:30 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., April 05, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
28. März 2023 07:30 ET
|
Zynerba Pharmaceuticals, Inc.
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted orphan drug...
Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank
13. März 2023 16:15 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
07. März 2023 07:00 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa, March 07, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference
01. März 2023 07:00 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
11. Januar 2023 08:30 ET
|
Zynerba Pharmaceuticals, Inc.
Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS) Cannabidiol...
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
21. Dezember 2022 07:00 ET
|
Zynerba Pharmaceuticals, Inc.
RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the “Tripledemic” (high rates of RSV, influenza and COVID-19); topline results now expected first half...
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
05. Dezember 2022 07:30 ET
|
Zynerba Pharmaceuticals, Inc.
Zygel™ achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment DEVON,...
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
29. November 2022 07:00 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...